BIOMARKERS FOR DEMENTIA DIAGNOSIS

VolverGo back

Resultados 64 results. LastUpdate Updated on 14/08/2022 [12:43:00] pdf PDF xls XLS

Solicitudes publicadas en los últimos 60 días / Applications published in the last 60 days



Page1/3 nextPage   results/page


DIAGNOSTIC METHOD BASED ON LARGE SCALE IDENTIFICATION OF POST-TRANSLATIONAL MODIFICATION OF PROTEINS

Publication No.: US2022252612A1 11/08/2022

Applicant:

HARVARD COLLEGE [US]

US_2015309044_A1

Absstract of: US2022252612A1

Methods for the large scale identification of post-translational modification states of proteins and enzyme activities for carrying out post-translational modification reactions involve the analysis of functional extracts from fresh and frozen samples using protein arrays. The methods and kits of the present invention can be used to analyze and characterize compounds for their effects on post-translational modifications and their pathways. The methods and kits can also be used to diagnose and characterize a wide variety of diseases and medical conditions, including cancer, neurodegenerative diseases, immune diseases, infectious diseases, genetic diseases, metabolic conditions, and drug effects using cells or body fluids of a patient.

traducir

APOLIPOPROTEIN E FRAGMENTS

Publication No.: US2022251171A1 11/08/2022

Applicant:

EISAI R&D MAN CO LTD [JP]
BIOARCTIC AB [SE]

CN_114008072_A

Absstract of: US2022251171A1

The present invention relates to novel fragments of apolipoprotein E (ApoE). These ApoE fragments have a variety of uses including as components of vaccine compositions, particularly vaccines for the prevention or treatment of neurological disorders such as Alzheimer's disease. The ApoE fragments may also be used in screening methods and methods of detection.

traducir

BIOMARKER FOR DIAGNOSIS OF CEREBRAL NERVOUS SYSTEM DISEASES

Publication No.: US2022252618A1 11/08/2022

Applicant:

IND ACADEMIC COOP FOUNDATION YONSEI UNIV [KR]
UNIV INDUSTRY COOP GROUP KYUNG HEE UNIV [KR]

KR_20200141401_A

Absstract of: US2022252618A1

The present invention relates to biomarkers capable of diagnosing various brain and nervous system diseases, and a method of providing information for diagnosing brain and nervous system diseases using the same. According to the present invention, it is possible to diagnose, at an early stage, the onset of a brain and nervous system disease or the likelihood of developing the disease or diagnose the progress or prognosis of the disease or the therapeutic effect against the disease, by measuring the expression level of the biomarker protein of the present invention or a gene encoding the same in the aqueous humor of the eye.

traducir

BLOOD INDICATORS OF ALZHEIMER'S DISEASE

Publication No.: WO2022168006A1 11/08/2022

Applicant:

THE INST FOR ETHNOMEDICINE DBA BRAIN CHEMISTRY LABS [US]

US_2022252620_A1

Absstract of: WO2022168006A1

Presented herein are methods of identifying a subject who has, or is at risk of developing Alzheimer's disease comprising determining a presence or amount of 2-aminoethyl dihydrogen phosphate or taurine in the blood, or a blood product, obtained from the subject. Also presented herein are method of preventing, treating or delaying the onset of Alzheimer's disease.

traducir

BLOOD INDICATORS OF ALZHEIMER'S DISEASE

Publication No.: US2022252620A1 11/08/2022

Applicant:

THE INST FOR ETHNOMEDICINE DBA BRAIN CHEMISTRY LABS [US]

WO_2022168006_A1

Absstract of: US2022252620A1

Presented herein are methods of identifying a subject who has, or is at risk of developing Alzheimer's disease comprising determining a presence or amount of 2-aminoethyl dihydrogen phosphate or taurine in the blood, or a blood product, obtained from the subject. Also presented herein are method of preventing, treating or delaying the onset of Alzheimer's disease.

traducir

ANTIBODIES TO PYROGLUTAMATE AMYLOID-β AND USES THEREOF

Publication No.: JP2022115986A 09/08/2022

Applicant:

ヤンセンファーマシューティカエヌ.ベー.

US_2021147528_A1

Absstract of: WO2018083628A1

The invention provides an antibody or antigen binding fragments thereof that binds to 3pE Aβ and methods of making and using the antibody or antigen binding fragment thereof, including use for formulations, administration and kits. The antibody and antigen binding fragments thereof and methods disclosed are useful for diagnosis, prognosis and treatment of Alzheimer's disease or other β-amyloid-related diseases.

traducir

TAU IMMUNOTHERAPY

Publication No.: JP2022116136A 09/08/2022

Applicant:

プロセナバイオサイエンシーズリミテッド

US_2021032319_A1

Absstract of: WO2017191559A1

The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.

traducir

ANTIBODY DIRECTED AGAINST THE APOE AMINO-TERMINAL FRAGMENT OF 12KDA

Publication No.: US2022242939A1 04/08/2022

Applicant:

BIOARCTIC AB [SE]

KR_20220029653_A

Absstract of: US2022242939A1

The disclosure relates to an antibody or antigen binding portion thereof, which binds to a neo-epitope of a C-terminal fragment of apolipoprotein E, to methods of producing such an antibody or antigen binding portion thereof, and to therapeutic and diagnostic uses thereof.

traducir

BIOMARKER FOR DIAGNOSIS OF DEMENTIA

Publication No.: WO2022163818A1 04/08/2022

Applicant:

UNIV TOHOKU [JP]

Absstract of: WO2022163818A1

A method for detecting a neurodegenerative disease in a subject, the method comprising measuring the level of two types of biomarkers including FABP3 and FABP5 in a biological sample from the subject.

traducir

METHOD FOR TREATMENT OF TRAUMATIC BRAIN INJURY TARGETING AGGREGATED PEPTIDES

Publication No.: JP2022113682A 04/08/2022

Applicant:

バイオアークティックアクティエボラーグ

JP_2018522891_A

Absstract of: WO2017013599A1

A method of preventing, alleviating or treating traumatic brain injury in an individual comprises administering to the individual a therapeutically effective and physiologically acceptable amount of an agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain. An agent capable of reducing the amount of one or more aggregated forms of one or more peptides in the brain is suitable for use in preventing, alleviating or treating traumatic brain injury. A method for predication of the risk of an individual for complications after a traumatic brain injury comprises detecting one or more aggregated forms of one or more peptides prone to aggregate as a result of a traumatic brain injury event, in the brain of the individual, wherein an increased level of such aggregates in the brain indicates an increased risk for complications.

traducir

HUMANIZED ANTI-ABETA MONOCLONAL ANTIBODY AND APPLICATION THEREOF

Publication No.: US2022242936A1 04/08/2022

Applicant:

CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD [CN]

JP_2022523517_A

Absstract of: US2022242936A1

Provided are a humanized anti-Aβ monoclonal antibody and use thereof. The humanized anti-Aβ monoclonal antibody provided can inhibit the polymerization of Aβ monomers, protect nerve cells from the toxicity of Aβ, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

traducir

NEURODEGENERATIVE DISEASE THERAPIES UTILIZING THE SKIN-BRAIN AXIS

Publication No.: US2022244275A1 04/08/2022

Applicant:

OHIO STATE INNOVATION FOUNDATION [US]

CN_114423413_PA

Absstract of: US2022244275A1

As disclosed herein, the skin can dispatch signals to the brain in the form of exosomes, referred to herein as a “skin-brain axis.” Therefore, disclosed herein is a method for diagnosing a brain disease, disorder, or injury in a subject that involves isolating exosomes from the subject and assaying the exosomes for the presence of one or more biomarkers of the disease, disorder, or injury. Also disclosed are methods of treating a subject with a brain disease, disorder, or injury that involves engineering the skin of the subject to produce therapeutic exosomes. Also disclosed are methods of collecting skin-produced exosomes and loading them with therapeutic cargo that can treat one or more diseases, disorders, or injuries of the brain. Also disclosed herein is a method to reduce exosomal release from the skin to reducing trafficking to the brain.

traducir

HUMANIZED ANTI-ABETA MONOCLONAL ANTIBODY AND APPLICATION THEREOF

Publication No.: US2022242937A1 04/08/2022

Applicant:

CHANGCHUN GENESCIENCE PHARMACEUTICAL CO LTD [CN]

JP_2022523516_A

Absstract of: US2022242937A1

Provided are a humanized anti-Aβ monoclonal antibody and use thereof. The humanized anti-Aβ monoclonal antibody provided can inhibit the polymerization of Aβ monomers, protect nerve cells from the toxicity of Aβ, and have a certain effect on improving the cognitive learning and memory ability of Alzheimer's dementia model mice, and can be used for the treatment and diagnosis of diseases and disorders related to amyloidosis, such as Alzheimer's disease.

traducir

COMPOUNDS AND METHODS TARGETING HUMAN TAU

Publication No.: JP2022534759A 03/08/2022

Applicant:

イーライリリーアンドカンパニー

US_2022146535_A1

Absstract of: WO2020242963A1

The present invention provides compounds and methods targeting human tau, particularly human tau phosphorylated at threonine (217) and isoforms of tau expressed only in the CNS, including therapeutic antibodies, pharmaceutical compositions and diagnostic applications useful in the field of neurodegenerative diseases such as AD, PSP and FTD.

traducir

CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO AND METHODS RELATED THEREOF

Publication No.: JP2022534406A 29/07/2022

Applicant:

ザユニヴァーシティオブブリティッシュコロンビア

US_2022218805_A1

Absstract of: WO2020237375A1

The disclosure pertains to conformational epitopes in oligomeric tau, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. The antibodies bind activity neutralizing sites in tau. Also provided are methods for making and using, including methods for treating a tauopathy.

traducir

Methods for Evaluation and Treatment of Alzheimer's Disease and Applications Thereof

Publication No.: US2022236294A1 28/07/2022

Applicant:

HUNTINGTON MEDICAL RES INSTITUTES [US]

CA_3141431_PA

Absstract of: US2022236294A1

Methods to determine risk of Alzheimer's disease and applications thereof are described. Generally, systems and methods utilize analyte measurements, such as dicarboxylic acid levels, to determine a risk of Alzheimer's disease. Based on Alzheimer disease risk, diagnostics or treatments can be performed.

traducir

METHODS FOR DETECTING CSF TAU SPECIES WITH STAGE AND PROGRESSION OF ALZHEIMER DISEASE, AND USE THEREOF

Publication No.: WO2022159766A1 28/07/2022

Applicant:

UNIV WASHINGTON [US]
BATEMAN RANDALL [US]
MCDADE ERIC [US]
BARTHELEMY NICOLAS [US]
HORIE KANTA [US]
LI YAN [US]

Absstract of: WO2022159766A1

The present disclosure provides methods to quantify and analyze various CSF Tau species and the use thereof to measure pathological features and/or clinical symptoms of tauopathies, including determining the amount of time to dementia due to Alzheimer's disease, determining the time from dementia onset, staging Alzheimer's disease, guiding treatment decisions, and evaluate the clinical efficacy of certain therapeutic interventions.

traducir

ANTIBODY ARRAY FOR MEASURING A PANEL OF AMYLOIDS

Publication No.: US2022236289A1 28/07/2022

Applicant:

MESO SCALE TECHNOLOGIES LLC [US]

Absstract of: US2022236289A1

Described are assay methods, modules and kits useful in the detection, treatment and/or prevention of dementia and related conditions, including but not limited to Alzheimer's disease and mild cognitive disorders.

traducir

ANTIBODY FOR DETECTING ACETYLATION OF COX2 PROTEIN, AND USES THEREOF

Publication No.: EP4032914A1 27/07/2022

Applicant:

KYUNGPOOK NAT UNIV IND ACADEMIC COOP FOUND [KR]

KR_20210034532_PA

Absstract of: EP4032914A1

The present invention relates to an antibody for detecting acetylation of COX2 protein, and uses thereof, and more specifically, to an antibody that specifically recognizes the acetylation of S565 residue of the COX2 protein; and uses thereof for diagnosing neurodegenerative diseases or inflammatory diseases. An antibody or a functional fragment thereof according to the present invention specifically binds to an acetylated residue of COX2 protein, and can thus be very effectively used for diagnosing neurodegenerative diseases, inflammatory diseases, and the like in which the degree of acetylation of S565 residue of the COX2 protein is reduced.

traducir

METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN

Publication No.: EP4031879A1 27/07/2022

Applicant:

AMYDIS INC [US]

CN_114729945_PA

Absstract of: WO2021055639A1

Provided herein are methods and compositions for determining whether a patient suffers from a neurological disease or disorder is provided, comprising detecting the presence of a phosphorylated tau protein in a tissue of the patient, wherein the detecting comprises contacting the phosphorylated tau protein with a compound described herein.

traducir

METHODS OF SCREENING FOR CONDENSATE-ASSOCIATED SPECIFICITY AND USES THEREOF

Publication No.: EP4031876A1 27/07/2022

Applicant:

DEWPOINT THERAPEUTICS INC [US]

CN_114729941_PA

Absstract of: WO2021055644A1

Methods of identifying a compound, such as a test compound, and applications thereof are provided. For example, methods of identifying a compound that preferentially affects, increases, or decreases a level of association of a macromolecule with one or more target condensates or methods of identifying a compound that preferentially causes a macromolecule to associate or disassociate with one or more target condensates are provided. Additionally, methods of designing and/or identifying and/or making a compound, or portion thereof, with a desired characteristic are provided.

traducir

BIOMARKERS AND USES THEREOF FOR DIAGNOSING THE SILENT PHASE OF ALZHEIMER'S DISEASE

Publication No.: KR20220104706A 26/07/2022

Applicant:

에전

AU_2020376239_PA

Absstract of: WO2021083977A1

The present invention relates to a molecular signature of the silent phase of Alzheimer's disease; and to methods using the same, for diagnosing a silent stage of Alzheimer's disease in a subject, stratifying a silent phase of Alzheimer's disease in a subject into different grades of the silent phase, prognosticating the progress of a silent phase of Alzheimer's disease in a subject, and determining a personalized course of treatment in a subject affected with a silent phase of Alzheimer's disease. It also relates to a computer system comprising a machine learning algorithm trained for diagnosing a silent phase of Alzheimer's disease in a subject.

traducir

ANTI-TDP-43 BINDING MOLECULES AND USES THEREOF

Publication No.: JP2022533432A 22/07/2022

Applicant:

エイシーイミューンソシエテアノニム

BR_112021023487_A2

Absstract of: WO2020234473A1

The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).

traducir

Determination agent and determination method for tauopathy and dementia-related diseases

Publication No.: AU2021217290A1 21/07/2022

Applicant:

SUMITOMO PHARMA CO LTD

TW_202136297_A

Absstract of: AU2021217290A1

The present invention provides a kit which is used to determine tauopathy and dementia-related diseases (here, Alzheimer's disease is excluded), and which comprises an antibody that recognizes a polypeptide consisting of: (1) the amino acid sequence represented by SEQ ID NO: 1; or (2) an amino acid sequence obtained by substituting, deleting, adding, or inserting one or more amino acids in the amino acid sequence represented by SEQ ID NO: 1.

traducir

METHODS FOR THE DETECTION AND TREATMENT OF PROTEINOPATHIES

Nº publicación: WO2022155322A1 21/07/2022

Applicant:

WOMEN & INFANTS HOSPITAL OF RHODE ISLAND [US]

Absstract of: WO2022155322A1

The present disclosure relates in part to a blood-based method for the detection of a proteinopathy in a subject including, but not limited to, Alzheimer's disease (AD), mild cognitive impairment (MCI), and preeclampsia (PE), utilizing autophagy-deficient trophoblast (ADT) cells to sequester protein aggregates from the serum of said subject, and permit detection thereof. The present disclosure further relates to methods of treating, preventing, and/or ameliorating a proteinopathy in a subject by the administration of trehalose, a salt, solvate, stereoisomer, derivative, prodrug and or any mixture thereof.

traducir

Page1/3 nextPage results/page

punteroimgGo back